Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESRRA | P11474 | 1/20 | 0.44 |
| ▸ | ESRRG | P62508 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31093170 | 0.84 | SLC6A4 (0.69) | SLC6A4SLC6A3SIGMAR1ALDH1A1 | |
| SCHEMBL1903553 | 0.81 | ALDH1A1 (0.62) | SLC6A4SLC6A3SIGMAR1ALDH1A1POLB | |
| SCHEMBL31092974 | 0.80 | SLC6A4 (0.54) | SLC6A4SLC6A3SIGMAR1ALDH1A1 | |
| SCHEMBL9779110 | 0.80 | ALDH1A1 (0.65) | SLC6A4SLC6A3SIGMAR1ALDH1A1POLB | |
| SCHEMBL31093121 | 0.79 | SLC6A4 (0.62) | SLC6A4SLC6A3SIGMAR1ALDH1A1POLB | |
| SCHEMBL31093199 | 0.77 | SLC6A4 (0.57) | SLC6A4SLC6A3SIGMAR1KDM4EALDH1A1 | |
| SCHEMBL31093117 | 0.76 | SLC6A4 (0.59) | SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL31093044 | 0.75 | SLC6A4 (0.52) | SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL31092907 | 0.74 | SLC6A4 (0.57) | SLC6A4SLC6A3SIGMAR1ALDH1A1 | |
| SCHEMBL31092931 | 0.74 | SLC6A4 (0.57) | SLC6A4SLC6A3SIGMAR1ALDH1A1ESRRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035497-A1 | AMINE CONTAINING COPOLYMERS VIA EMULSION POLYMERIZATION AND METHODS OF USE THEREOF | INFINEUM INTERNATIONAL LIMITED (US) | 2026-02-05 | — | — | US | claimed |
| US-20260035493-A1 | AMINE CONTAINING COPOLYMERS VIA RADICAL POLYMERIZATION AND METHODS OF USE THEREOF | INFINEUM INTERNATIONAL LIMITED (US) | 2026-02-05 | — | — | US | claimed |
| US-20260028457-A1 | AMINE CONTAINING COPOLYMER EMULSION COMPOSITIONS AND METHODS OF MAKING AND USE THEREOF | INFINEUM INTERNATIONAL LIMITED (US) | 2026-01-29 | — | — | US | claimed |
| US-20250250379-A1 | AMINE CONTAINING POLYMER COMPOSITIONS AND USES THEREOF | INFINEUM INTERNATIONAL LIMITED (US) | 2025-08-07 | — | — | US | claimed |
| EP-4596661-A1 | AMINE CONTAINING POLYMER COMPOSITIONS AND USES THEREOF | Infineum International Limited (GB) | 2025-08-06 | — | — | EP | claimed |
| US-20240287009-A1 | AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME | INFINEUM INTERNATIONAL LIMITED (GB) | 2024-08-29 | — | — | US | claimed |
| EP-4410772-A2 | AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME | Infineum International Limited (GB) | 2024-08-07 | — | — | EP | claimed |
| CN-118440229-A | Amine functional monomers and methods of making the same | 英菲诺姆国际有限公司 | 2024-08-06 | — | — | CN | claimed |
| US-20260035497-A1 | AMINE CONTAINING COPOLYMERS VIA EMULSION POLYMERIZATION AND METHODS OF USE THEREOF | INFINEUM INTERNATIONAL LIMITED (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260035495-A1 | FUNCTIONAL COPOLYMERS AND METHODS OF PREPARATION THEREOF | Kraton Corporation (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260035493-A1 | AMINE CONTAINING COPOLYMERS VIA RADICAL POLYMERIZATION AND METHODS OF USE THEREOF | INFINEUM INTERNATIONAL LIMITED (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260028457-A1 | AMINE CONTAINING COPOLYMER EMULSION COMPOSITIONS AND METHODS OF MAKING AND USE THEREOF | INFINEUM INTERNATIONAL LIMITED (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250250379-A1 | AMINE CONTAINING POLYMER COMPOSITIONS AND USES THEREOF | INFINEUM INTERNATIONAL LIMITED (US) | 2025-08-07 | — | — | US | disclosed |
| EP-4596661-A1 | AMINE CONTAINING POLYMER COMPOSITIONS AND USES THEREOF | Infineum International Limited (GB) | 2025-08-06 | — | — | EP | disclosed |
| US-20240287009-A1 | AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME | INFINEUM INTERNATIONAL LIMITED (GB) | 2024-08-29 | — | — | US | disclosed |
| EP-4410772-A2 | AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME | Infineum International Limited (GB) | 2024-08-07 | — | — | EP | disclosed |
| CN-118440229-A | Amine functional monomers and methods of making the same | 英菲诺姆国际有限公司 | 2024-08-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035495-A1 | FUNCTIONAL COPOLYMERS AND METHODS OF PREPARATION THEREOF | VCL, FGB, CDH1 | SLC6A4 4190/4885SLC6A3 3824/4885SIGMAR1 306/4885 |
| US-20260035493-A1 | AMINE CONTAINING COPOLYMERS VIA RADICAL POLYMERIZATION AND METHODS OF USE THEREOF | CBS, SELP, RAD51 | SLC6A4 967/4885SLC6A3 1604/4885SIGMAR1 240/4885 |
| US-20240287009-A1 | AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME | AMD1, HNMT, MAT1A | SLC6A4 2274/4885SLC6A3 2219/4885SIGMAR1 2501/4885 |
| US-20260035497-A1 | AMINE CONTAINING COPOLYMERS VIA EMULSION POLYMERIZATION AND METHODS OF USE THEREOF | DEGS1, SGMS1, PHOSPHO1 | SLC6A4 2459/4885SLC6A3 3038/4885SIGMAR1 69/4885 |
| US-20260028457-A1 | AMINE CONTAINING COPOLYMER EMULSION COMPOSITIONS AND METHODS OF MAKING AND USE THEREOF | DEGS1, PHOSPHO1, NAPEPLD | SLC6A4 3112/4885SLC6A3 2986/4885SIGMAR1 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.